Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 17Iodine-131 16lenvatinib 13trametinib 12Thyrotropin Alfa 11Sorafenib 11pembrolizumab 10dabrafenib 10Paclitaxel 9vandetanib 8Thyroxine 8Surgical Procedures, Operative 7Sunitinib 7selpercatinib 6cabozantinib 6Nivolumab 6Fluorodeoxyglucose F18 6Everolimus 6pazopanib 5Vemurafenib 5Thyroidectomy 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Cyclophosphamide 5Cisplatin 5Biopsy 5apatinib 4anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Neoplasms × CUDC-907 × Clear all
NCT03002623 2018-12-21

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
7 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡